Michael A. Feuerstein

Michael A. Feuerstein

Auto-generated profile, based on publicly available information

Michael A. Feuerstein

Lenox Hill Hospital, Zucker School of Medicine at Hofstra/Northwell

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2004 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
NCNichola Cooper
Nichola Cooper
RSRoberto Stasi
Roberto Stasi
SCSusanna Cunningham‐Rundles
Susanna Cunningham‐Rundles
MFMichael A. Feuerstein
Michael A. Feuerstein
JLJohn P. Leonard
John P. Leonard
JBJames B. Bussel
James B. Bussel
Summary: Because of its B‐cell depleting effect, rituximab has entered clinical trials in several autoimmune conditions. This study assesses the efficacy and safety of rituximab in 57 adults with chronic immune thrombocytopenic purpura (ITP). All patients had platelet counts 50 × 109/l: 18 achieved a complete response (CR: platelet count >150 × 109/l) and 13 a partial response (PR: platelet count 50–150 × 109/l). Twenty‐nine responses occurred within 8 weeks of the first infusion. Sixteen of 18 CR patients (28% overall), including eight who had failed splenectomy, continued in CR after a median of 72·5 weeks; 15 of 16 are >1 year from the first infusion. Only two of 13 maintained a PR. Thirty‐three patients experienced grade 1–2 adverse events and one a grade 3 event, but they all completed treatment. Circulating B cells fell to <0·03 × 109/l. No changes in immunoglobulin levels or infectious complications were seen. In summary, rituximab was well tolerated with no immediate complications and induced a lasting, substantial response in 32% of adults with chronic ITP.

1 February 2005 in The Journal of Pediatrics
Verified
Journal Article
Closed access
JWJulie Wang
Julie Wang
JWJoseph M. Wiley
Joseph M. Wiley
RLRuth Luddy
Ruth Luddy
JGJay Greenberg
Jay Greenberg
MFMichael A. Feuerstein
Michael A. Feuerstein
JBJames B. Bussel
James B. Bussel

1 September 2014 in European Urology
Verified
Journal Article
Closed access
FEFabio Efficace
Fabio Efficace
MFMichael Feuerstein
Michael Feuerstein
PFPeter Fayers
Peter Fayers
VCValentina Cafaro
Valentina Cafaro
JEJames Eastham
James Eastham
JBJane Blazeby
Jane Blazeby

26 April 2010 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
MCMengqian Chen
Mengqian Chen
MFMichael A. Feuerstein
Michael A. Feuerstein
ELElina Levina
Elina Levina
PBPrateek S. Baghel
Prateek S. Baghel
RCRichard D. Carkner
Richard D. Carkner
RBRalph Buttyan
Ralph Buttyan
Background: Castration resistant prostate cancer (CRPC) develops as a consequence of hormone therapies used to deplete androgens in advanced prostate cancer patients. CRPC cells are able to grow in a low androgen environment and this is associated with anomalous activity of their endogenous androgen receptor (AR) despite the low systemic androgen levels in the patients. Therefore, the reactivated tumor cell androgen signaling pathway is thought to provide a target for control of CRPC. Previously, we reported that Hedgehog (Hh) signaling was conditionally activated by androgen deprivation in androgen sensitive prostate cancer cells and here we studied the potential for cross-talk between Hh and androgen signaling activities in androgen deprived and androgen independent (AI) prostate cancer cells. Results: Treatment of a variety of androgen-deprived or AI prostate cancer cells with the Hh inhibitor, cyclopamine, resulted in dose-dependent modulation of the expression of genes that are regulated by androgen. The effect of cyclopamine on endogenous androgen-regulated gene expression in androgen deprived and AI prostate cancer cells was consistent with the suppressive effects of cyclopamine on the expression of a reporter gene (luciferase) from two different androgen-dependent promoters. Similarly, reduction of smoothened (Smo) expression with siRNA co-suppressed expression of androgen-inducible KLK2 and KLK3 in androgen deprived cells without affecting the expression of androgen receptor (AR) mRNA or protein. Cyclopamine also prevented the outgrowth of AI cells from androgen growth-dependent parental LNCaP cells and suppressed the growth of an overt AI-LNCaP variant whereas supplemental androgen (R1881) restored growth to the AI cells in the presence of cyclopamine. Conversely, overexpression of Gli1 or Gli2 in LNCaP cells enhanced AR-specific gene expression in the absence of androgen. Overexpressed Gli1/Gli2 also enabled parental LNCaP cells to grow in androgen depleted medium. AR protein co-immunoprecipitates with Gli2 protein from transfected 293T cell lysates. Conclusions: Collectively, our results indicate that Hh/Gli signaling supports androgen signaling and AI growth in prostate cancer cells in a low androgen environment. The finding that Gli2 co-immunoprecipitates with AR protein suggests that an interaction between these proteins might be the basis for Hedgehog/Gli support of androgen signaling under this condition.

5 September 2015 in Current Urology Reports
Verified
Journal Article
Closed access
PDF file
MFMichael A. Feuerstein
Michael A. Feuerstein
AGAnuj Goenka
Anuj Goenka

9 January 2014 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
MFMichael A. Feuerstein
Michael A. Feuerstein
MKMatthew Kent
Matthew Kent
WBWassim M. Bazzi
Wassim M. Bazzi
MBMelanie Bernstein
Melanie Bernstein
PRPaul Russo
Paul Russo